Literature DB >> 20110440

Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice.

Deepa Taneja1, Joel Thompson, Patricia Wilson, Katie Brandewie, Liliana Schaefer, Bonnie Mitchell, Lisa R Tannock.   

Abstract

Hyperlipidemia is a risk factor for development and progression of diabetic nephropathy. However, it is not known if reduction of hyperlipidemia is protective against progression of disease. The goal of this study was to determine if reduction of hypercholesterolemia could limit progression of diabetic nephropathy. Diabetic and nondiabetic LDL receptor deficient (LDLR(-/-)) mice were fed diets containing either no cholesterol (0%) or high cholesterol (0.12%) for 36 weeks. One group each of diabetic and nondiabetic mice were fed the high-cholesterol diet for 26 weeks then changed to the 0% cholesterol diet for the last 10 weeks. Consumption of the high-cholesterol diet exacerbated the development of diabetic nephropathy with elevations in urine albumin excretion, glomerular and renal hypertrophy, and mesangial matrix expansion. Increased glomerular lipid and apolipoprotein B accumulation was found in diabetic mice that consumed the 0.12% cholesterol diet compared with other groups. However, diabetic mice that changed from the high-cholesterol diet to the 0% cholesterol diet for the last 10 weeks had lower urine albumin excretion and mesangial matrix expansion compared with mice that consumed the 0.12% cholesterol diet throughout. This suggests that hyperlipidemia causes continuous renal injury, and that lowering cholesterol levels by dietary means can improve renal function in diabetic LDLR(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110440      PMCID: PMC3035509          DOI: 10.1194/jlr.M002972

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  32 in total

1.  Low density lipoproteins transactivate EGF receptor: role in mesangial cell proliferation.

Authors:  Vaijinath S Kamanna; Babu V Bassa; Shobha H Ganji
Journal:  Life Sci       Date:  2008-09-06       Impact factor: 5.037

2.  Low-density lipoprotein stimulates mesangial cell proteoglycan and hyaluronan synthesis.

Authors:  R S Chana; D C Wheeler; G J Thomas; J D Williams; M Davies
Journal:  Nephrol Dial Transplant       Date:  2000-02       Impact factor: 5.992

Review 3.  Dyslipidemia and the progression of renal disease in chronic renal failure patients.

Authors:  Aleix Cases; Elisabet Coll
Journal:  Kidney Int Suppl       Date:  2005-12       Impact factor: 10.545

4.  Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure.

Authors:  Ognen Ivanovski; Dorota Szumilak; Thao Nguyen-Khoa; Igor G Nikolov; Nobuhiko Joki; Nadya Mothu; Julien Maizel; Ralf Westenfeld; Marcus Ketteler; Bernard Lacour; Tilman B Drüeke; Ziad A Massy
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

5.  Effect of statins on the development of renal dysfunction.

Authors:  Rishi Sukhija; Zoran Bursac; Priyanka Kakar; Louis Fink; Charlton Fort; Shiyam Satwani; Wilbert S Aronow; Darpan Bansal; Jawahar L Mehta
Journal:  Am J Cardiol       Date:  2008-01-25       Impact factor: 2.778

6.  Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development.

Authors:  Fei Huang; Joel C Thompson; Patricia G Wilson; Hnin H Aung; John C Rutledge; Lisa R Tannock
Journal:  J Lipid Res       Date:  2007-11-21       Impact factor: 5.922

7.  Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases.

Authors:  T Takemura; K Yoshioka; N Aya; K Murakami; A Matumoto; H Itakura; T Kodama; H Suzuki; S Maki
Journal:  Kidney Int       Date:  1993-04       Impact factor: 10.612

8.  Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice.

Authors:  M Fujii; T Inoguchi; Y Maeda; S Sasaki; F Sawada; R Saito; K Kobayashi; H Sumimoto; R Takayanagi
Journal:  Kidney Int       Date:  2007-06-13       Impact factor: 10.612

9.  Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway.

Authors:  Satoru Sharyo; Naoko Yokota-Ikeda; Miyuki Mori; Kazuyoshi Kumagai; Kazuyuki Uchida; Katsuaki Ito; Melissa J Burne-Taney; Hamid Rabb; Masahiro Ikeda
Journal:  Kidney Int       Date:  2008-05-28       Impact factor: 10.612

Review 10.  Mouse models for atherosclerosis and pharmaceutical modifiers.

Authors:  Susanne Zadelaar; Robert Kleemann; Lars Verschuren; Jitske de Vries-Van der Weij; José van der Hoorn; Hans M Princen; Teake Kooistra
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-05-31       Impact factor: 8.311

View more
  8 in total

1.  Elevated circulating TGF-β is not the cause of increased atherosclerosis development in biglycan deficient mice.

Authors:  Joel C Thompson; Patricia G Wilson; Alex P Wyllie; Adrian K Wyllie; Lisa R Tannock
Journal:  Atherosclerosis       Date:  2017-11-10       Impact factor: 5.162

2.  Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF-β inhibition.

Authors:  Patricia G Wilson; Joel C Thompson; Meghan H Yoder; Richard Charnigo; Lisa R Tannock
Journal:  J Lipid Res       Date:  2017-09-14       Impact factor: 5.922

3.  Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy.

Authors:  Joel Thompson; Patricia Wilson; Katie Brandewie; Deepa Taneja; Liliana Schaefer; Bonnie Mitchell; Lisa R Tannock
Journal:  Am J Pathol       Date:  2011-06-30       Impact factor: 4.307

4.  Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats.

Authors:  Feng Ling Wang; Li Qin Tang; Feng Yang; Ling Na Zhu; Ming Cai; Wei Wei
Journal:  Mol Biol Rep       Date:  2012-11-30       Impact factor: 2.316

5.  Early systemic microvascular damage in pigs with atherogenic diabetes mellitus coincides with renal angiopoietin dysbalance.

Authors:  Meriem Khairoun; Mieke van den Heuvel; Bernard M van den Berg; Oana Sorop; Rients de Boer; Nienke S van Ditzhuijzen; Ingeborg M Bajema; Hans J Baelde; Malu Zandbergen; Dirk J Duncker; Ton J Rabelink; Marlies E J Reinders; Wim J van der Giessen; Joris I Rotmans
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

6.  An ACACB variant implicated in diabetic nephropathy associates with body mass index and gene expression in obese subjects.

Authors:  Lijun Ma; Mariana Murea; James A Snipes; Alejandra Marinelarena; Jacqueline Krüger; Pamela J Hicks; Kurt A Langberg; Meredith A Bostrom; Jessica N Cooke; Daisuke Suzuki; Tetsuya Babazono; Takashi Uzu; Sydney C W Tang; Ashis K Mondal; Neeraj K Sharma; Sayuko Kobes; Peter A Antinozzi; Matthew Davis; Swapan K Das; Neda Rasouli; Philip A Kern; Nathan J Shores; Lawrence L Rudel; Matthias Blüher; Michael Stumvoll; Donald W Bowden; Shiro Maeda; John S Parks; Peter Kovacs; Robert L Hanson; Leslie J Baier; Steven C Elbein; Barry I Freedman
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

7.  Combining streptozotocin and unilateral nephrectomy is an effective method for inducing experimental diabetic nephropathy in the 'resistant' C57Bl/6J mouse strain.

Authors:  Melissa Uil; Angelique M L Scantlebery; Loes M Butter; Per W B Larsen; Onno J de Boer; Jaklien C Leemans; Sandrine Florquin; Joris J T H Roelofs
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

8.  Apolipoprotein B and renal function: across-sectional study from the China health and nutrition survey.

Authors:  Wenbo Zhao; Junqing Li; Xiaohao Zhang; Xiaomei Zhou; Junyi Xu; Xun Liu; Zifeng Liu
Journal:  Lipids Health Dis       Date:  2020-05-27       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.